AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use [Yahoo! Finance]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
approval of its PD-L1 inhibitor Imfinzi (durvalumab) as a treatment for certain patients with primary advanced or recurrent endometrial cancer. The CHMP recommended the approval of Imfinzi plus chemotherapy, followed by Imfinzi and Lynparza as a first-line treatment for patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer. The CHMP has also recommended the approval of Imfinzi plus chemotherapy, followed by Imfinzi monotherapy for the treatment of patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer. The CHMP's positive opinion of both regimens was based on data from a prespecified exploratory subgroup analysis by MMR status in the phase III DUO-E study. Data from the Lynparza plus Imfinzi arm showed a reduction in the risk of disease progression or death by 43% in pMMR patients versus the control arm. Meanwhile, the Imfinzi arm showed a reduction in the risk of disease progression or death by 58% for dMMR p
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock [Yahoo! Finance]Yahoo! Finance
- AstraZeneca & Aptamer partner to bolster targeted siRNA therapies [Yahoo! Finance]Yahoo! Finance
- AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC [Yahoo! Finance]Yahoo! Finance
- AstraZeneca's Tagrisso plus chemotherapy wins EU approval for NSCLC [Yahoo! Finance]Yahoo! Finance
- Innovent sells its share in CAR T-cell therapy to IASO Bio for 18% equity [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 7/1/24 - Form 6-K
- 7/1/24 - Form 6-K
- 6/26/24 - Form 11-K
- AZN's page on the SEC website